Ertapenem

• Invanz
• (4R, 5S, 6S ) -3 - [ (3S, 5S ) -5 - [(3- carboxyphenyl) carbamoyl] pyrrolidin- 3-yl] sulfanyl -6-( 1 -hydroxyethyl )-4- methyl-7- oxo-1- azabicyclo [3.2.0 ] hept -2- ene- 2 -carboxylic acid

J01DH03

β -lactam antibiotics, carbapenem

Inhibition of cell wall synthesis

Template: Infobox chemical / molecular formula search available

Ertapenem is a drug that belongs to the group of carbapenems.

Pharmacology

Ertapenem is administered parenterally and is approved for adults and children from the age of 3 months for the treatment of intra-abdominal infections, community-acquired pneumonia and gynecological infections and infections on the foot in diabetic patients.

According to the mode of action of the older carbapenems ertapenem is also rapidly bactericidal effect and shows a time-dependent Tötungskinetik; That is, a minimum effective concentration in the body must be exceeded permanently. It is against almost every other stable beta-lactamases, including the " AmpC cephalosporinase " and the extended-spectrum - β -lactamases (ESBL ); unlike imipenem also against the dehydropeptidase I.

Spectrum of activity

As carbapenem ertapenem acts against both Gram-positive and -negative bacteria as well as against some anaerobes, but in comparison to its predecessors, a narrower spectrum. Ertapenem is ineffective against Pseudomonas aeruginosa and Enterococcus. In general, meropenem and ertapenem against gram - negative area look a bit better than imipenem.

Side effects

The side effects are similar to those of penicillins and cephalosporins.

Trade names

Invanz (EU, CH)